BioXcel Therapeutics
BTAI
104 hedge funds and large institutions have $431M invested in BioXcel Therapeutics in 2020 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 10 closing their positions.
340% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 10
269% more capital invested
Capital invested by funds: $117M → $431M (+$314M)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
110% more call options, than puts
Call options by funds: $27.9M | Put options by funds: $13.3M
70% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 20
49% more funds holding
Funds holding: 70 → 104 (+34)
0.65% more ownership
Funds ownership: 1.86% → 2.51% (+0.65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$34.6M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$20.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.8M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$12.2M |
| 5 |
BlackRock
New York
|
+$9.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.9M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$17.3M |
| 3 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$3.48M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$3.23M |
| 5 |
MAP
Moody Aldrich Partners
Marblehead,
Massachusetts
|
-$2.46M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWM
101
Geneos Wealth Management
Englewood,
Colorado
| $5K | – | – | – |
|
|
GEA
102
Glen Eagle Advisors
Kingston,
New Jersey
| $1.32K | +$1.3K | +2 | New |
|
|
PWP
103
Principle Wealth Partners
Madison,
Connecticut
| $1K | +$652 | +1 | New |
|
|
O
104
OrbiMed
New York
| – | -$2.4M | -6,706 | Closed |
|
|
HP
105
Hound Partners
New York
| – | -$782K | -2,188 | Closed |
|
|
LCM
106
Laurion Capital Management
New York
| – | -$671K | -1,875 | Closed |
|
|
CBA
107
Coastal Bridge Advisors
Westport,
Connecticut
| – | -$559K | -1,563 | Closed |
|
108
Squarepoint
New York
| – | -$322K | -901 | Closed |
|
109
Creative Planning
Overland Park,
Kansas
| – | -$244K | -682 | Closed |
|
|
DCM
110
DAFNA Capital Management
Los Angeles,
California
| – | -$103K | -288 | Closed |
|
|
AWM
111
AllSquare Wealth Management
Albany,
New York
| – | -$22K | -61 | Closed |
|
|
ASN
112
Advisory Services Network
Atlanta,
Georgia
| – | -$7K | -19 | Closed |
|
|
GWS
113
Glassman Wealth Services
Vienna,
Virginia
| – | +$652 | +1 | New |
|
BTAI Hedge Fund Activity: Q2 2020 in Review
104 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2020, worth a combined $431M — up 269% from $117M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new BTAI positions and 10 closed out — a net gain of 34 holders — while 34 added to existing stakes and 20 trimmed.
The largest buyer was State Street, adding an estimated $34.6M. The largest seller was Fidelity Investments, cutting an estimated $17.9M.
- 104 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2020, up from 70 in Q1 2020.
- Funds reported $431M of BioXcel Therapeutics stock for Q2 2020, up 269% quarter-over-quarter.
- 44 funds opened new BioXcel Therapeutics positions in Q2 2020 and 10 closed out, a net change of +34 holders.
- The largest BioXcel Therapeutics buyer in Q2 2020 was State Street, an estimated $34.6M added.
- The largest BioXcel Therapeutics seller in Q2 2020 was Fidelity Investments, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2020.